Global Antifungal
Drugs Market, by Drug Type (Echinocandins, Polyenes, Allylamines, Azoles,
and Others), By Indication (Aspergillosis, Dermatophytosis, Candidiasis, and
Others), By Dosage Form (Powders, Ointments, Drugs, and Others), and by Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
is estimated to be valued at US$ 11,591.0 million in 2020 and is expected to
exhibit a CAGR of 1.8% during the forecast period (2020-2027), as highlighted
in a new report published by Coherent Market Insights.
Global Antifungal Drugs Market -
Impact of Coronavirus (COVID-19) Pandemic
The outbreak of COVID-19 has
created challenges for several industries and markets worldwide. Due to rise in
COVID 19, society and healthcare facilities have paid more attention to the
healthcare industry, which will impose both positive and negative impact across
its different sub-sectors. In the short term, the pharma companies, healthcare
institutions, pharmaceutical distribution and retail have negative impact of
covid-19 spread. According World Health Organization, in December 2019, the
manifestation of coronavirus disease (COVID-19) has resulted in more than 29.6
million infected individuals worldwide as of September 2020. The COVID-19 pandemic
has affected the global economy in three main ways; by directly affecting
production and demand, by negatively impacting the supply chain and market
disruption, and through its financial impact on firms and financial markets.
This negative economic impact is expected to hamper growth of various
pharmaceutical markets which includes the antifungal drugs market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/237
Moreover, severe economic crisis
and broken supply chain is a major issue faced by players operating in the
antifungal drug market across globe. The pandemic has negatively impacted the
medical healthcare industry in terms services provided by healthcare
facilities. As a result, the global antifungal drugs market growth is also
expected to witness a slowdown till the period of COVID-19 control. Major
pharmaceutical companies are focused on developing vaccines for treating
COVID-19.
Browse 28 Market Data Tables and
25 Figures spread through 149 Pages and in-depth TOC on Global Antifungal Drugs
Market, by Drug Type (Echinocandins, Polyenes, Allylamines, Azoles, Others) By
Indication (Aspergillosis, Dermatophytosis, Candidiasis, Others) By Dosage
Forms (Powders, Ointments, Drugs, Others) and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa), - Forecast to 2027"
Moreover, key players in the
market are involved in various growth strategies such as gaining product
approval from regulatory authorities, in order to strengthen their market
presence. For instance, in February 2018, Insmed, Inc., a biopharmaceutical
company, received the U.S. Food and Drugs Administration (FDA) approval for a
new drug called Arikayce (amikacin liposome inhalation suspension) which was
approved limited population pathway for antibacterial and antifungal drugs
program.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/anti-fungal-drugs-market-237
Key Takeaways of the Global
Antifungal Drugs Market:
The global antifungal drugs
market is expected to exhibit a CAGR of 1.8% during the forecast period
(2020-2027) owing to launches of antifungal drugs for fungal infection
treatment.
Among drug type, the
Echinocandins segment is expected to hold a major revenue share in 2027 owing
to launches of this drug type. For instance, in 2018, Hansoh Pharma launched
echinocandins antifungal drug Hengsen (micafungin sodium for injection).
Major players operating in the
global antifungal drugs market are GlaxoSmithKline Plc, Bayer AG, Abbott
Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon
Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A. and
Astellas Pharma, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/237
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment